Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABS 1230

Next Previous
Drug Profile

ABS 1230

Alternative Names: ABS-1230

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actio Biosciences
  • Class Antiepileptic drugs; Small molecules
  • Mechanism of Action KCNT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 23 Sep 2025 Actio Biosciences plans a proof-of-concept phase Ib/IIa trial for Epilepsy in US in early 2026
  • 28 Aug 2025 Phase-I clinical trials in Epilepsy (In volunteers, In adults) in Australia (PO) (NCT07156201)
  • 30 Jul 2025 ABS 1230 receives Fast Track designation for Epilepsy [PO] in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top